12 Results for "

diabetic macular edema

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "diabetic macular edema" in MCE Product Catalog:

Cat. No.: HY-P99116
CAS No.: 1607793-29-2
Synonyms: RG7716; RO-6867461
Faricimab, an overall good safety and tolerability profile, is a bispecific antibody targeting Angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A). Faricimab prevents retinal vascular leakage, cell death and inflammation in retinal ischemia/reperfusion (I/R) injury and sCNV mouse models. Faricimab demonstrates statistically superior visual acuity gains versus Ranibizumab (HY-P9951). Faricimab can be used for retinal diseases, such as age-related macular degeneration (w-AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO) .
loading...
    loading...
Cat. No.: HY-136642
CAS No.: 807-38-5
Purity:  99.66%
Research Areas:  

Inflammation/Immunology

Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
loading...
    loading...
Cat. No.: HY-P99830
CAS No.: 1227158-72-6
Synonyms: KH902
Conbercept (KH902) is a recombinant fusion protein composed of VEGFR-1 (second domain) and VEGFR-2 (third and fourth domains) regions fused to human IgG1 Fc. Conbercept is a VEGF inhibitor (IC50 = 8.8 pM) and is a soluble receptor decoy that blocks all isoforms of VEGF-A (Kd = 0.5 pM), VEGF-B (Kd = 8 pM), VEGF-C, and PlGF (Kd = 5 pM). Conbercept has anti-inflammatory effects, can lower the levels of VEGF, TNF-α and IL-6, and reduce the infiltration of inflammatory cells. Conbercept decreases tumor growth in several oncology studies. Conbercept can be used for various eye diseases such as polypoidal choroidal vasculopathy (PCV), diabetic macular edema (DME) and pathologic myopia choroidal neovascularization (pmCNV) .
loading...
    loading...
Cat. No.: HY-W662576
CAS No.: 1417691-95-2
KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research .
loading...
    loading...
Cat. No.: HY-117621A
CAS No.: 2140301-98-8
Purity:  99.50%
Target:  

CCR

Research Areas:  

Metabolic Disease

PF-0463481 succinate is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM). PF-0463481 succinate is safe and well-tolerated and has the potential for the study of diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-117621
CAS No.: 1228111-63-4
Target:  

CCR

Research Areas:  

Metabolic Disease

PF-0463481 is a potent and orally active dual CCR2/CCR5 antagonist with comparable human and rodent CCR2 potency (rat IC50=20.8 nM), and displays 10-20 fold less rodent CCR5 potency (rat IC50=470 nM). PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy .
loading...
    loading...
Cat. No.: HY-150052
CAS No.: 1357950-47-0
Target:  

Kallikrein

Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
loading...
    loading...
Cat. No.: HY-143476
Target:  

Kallikrein

Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
loading...
    loading...
Cat. No.: HY-P991293

Target:  

c-Kit

Research Areas:  

Metabolic Disease

NN-2101 is a human monoclonal antibody (mAb) targeting c-Kit/CD117. NN-2101 is used in the research of retinal disorders and diabetic macular edema.
loading...
    loading...
Cat. No.: HY-181798
CAS No.: 2773609-90-6
Target:  

Kallikrein

Research Areas:  

Metabolic Disease

pKal-IN-1 (compound 13) is a plasma kallikrein (pKal) inhibitor. pKal-IN-1 can be used for the research of diabetic macular edema, diabetic retinopathy .
loading...
    loading...
Cat. No.: HY-136642R
CAS No.: 807-38-5
Fluocinolone (Standard) is the analytical standard of Fluocinolone (HY-136642). This product is intended for research and analytical applications. Fluocinolone is a potent steroid with highly selective glucocorticoid receptor agonist activity. Fluocinolone stabilizes the blood-retinal barrier by enhancing endothelial tight junctions, inhibiting the VEGF pathway and inflammatory factors. Fluocinolone has high lipophilicity, enabling long-term sustained release in the vitreous. Fluocinolone is used in research related to dermatological diseases, diabetic macular edema, uveitis and oral lichen planus .
loading...
    loading...
Cat. No.: HY-P992126
CAS No.: 3059389-31-7
Synonyms: EYE-103; MK-3000
Target:  

Wnt

Research Areas:  

Neurological Disease

Remigromig (EYE-103; MK-3000) is a humanized dual-target monoclonal antibody that targets LRP5 and FZD4. Remigromig activates the Wnt/β-catenin signaling pathway by mimicking the natural ligand Norrin, induces tight junction formation and restores blood-retinal barrier function. Administered via intravitreal injection, Remigromig reduces retinal vascular leakage, and demonstrates improvements in best-corrected visual acuity and reductions in retinal thickness in studies of diabetic macular edema. Remigromig can be used for research related to macular degeneration .
loading...
    loading...
  • 1